Table 2 Treatment strategies at baseline and last follow-up
Treatment strategies, n (%) of patients with | At baseline evaluation | At last persistence evaluation |
|---|---|---|
Oral corticosteroids | 42 (36.5) | 48 (41.7) |
Methotrexate monotherapy | 20 (17.4) | 43 (37.4) |
2 combined DMARDs (methotrexate required) | 68 (59.1) | 40 (34.8) |
≥3 combined DMARDs (methotrexate required) | 21 (18.3) | 22 (19.1) |
Other combinations of traditional DMARDs | 6 (5.2) | 10 (8.7) |
Biologic DMARDs | 0 | 5 (4.3) |